Important Investor Alert: Levi & Korsinsky, LLP Announces a Securities Class Action Lawsuit Against BioAge Labs, Inc.
NEW YORK, Feb. 21, 2025 – Levi & Korsinsky, LLP announces that a class action securities lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of shareholders of BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA).
Background
BioAge is a biotechnology company focused on developing and commercializing therapies for aging and age-related diseases. The Company’s lead product candidate, BIO-01, is a senolytic drug designed to eliminate senescent cells, which are believed to contribute to aging and various age-related diseases.
Allegations
The complaint alleges that throughout the class period, BioAge made false and misleading statements and failed to disclose material information to investors. Specifically, the Company allegedly made false and/or misleading statements and/or failed to disclose that:
- BIO-01’s clinical trial data was flawed and inadequate;
- The Company had insufficient data to support the safety and efficacy of BIO-01;
- The Company had not obtained regulatory approval for the clinical trials;
- The Company had not disclosed the true nature and extent of the regulatory issues with BIO-01;
- The Company had overstated the commercial potential of BIO-01.
Impact on Individual Investors
If you purchased or otherwise acquired BioAge securities during the class period, you may be entitled to recover your losses, including damages. The deadline to move for lead plaintiff status is April 20, 2025. To obtain more information, contact Levi & Korsinsky, LLP.
Impact on the World
The outcome of this lawsuit could have significant implications for the biotech industry and the development of senolytic drugs. If the allegations are proven true, it could lead to increased scrutiny of clinical trial data and regulatory approval processes in the industry. It could also potentially discourage investment in biotech companies focusing on aging and age-related diseases.
Conclusion
The securities lawsuit against BioAge Labs, Inc. highlights the importance of accurate and transparent disclosures in the biotech industry. It also serves as a reminder for investors to carefully evaluate the clinical trial data and regulatory approval processes of companies before investing. If you are a BioAge shareholder and believe you may have lost money as a result of the Company’s alleged misconduct, contact Levi & Korsinsky, LLP for more information.
Levi & Korsinsky, LLP is a national law firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, accounting fraud, and materially misleading statements. For more information, please contact Levi & Korsinsky, LLP.
This communication is not a law firm advertisement and is not intended as legal advice or opinion. It is not a solicitation for any particular investment or participation in any securities offering. Any securities mentioned in this communication are not offered or sold by Levi & Korsinsky, LLP or its affiliates.
Levi & Korsinsky, LLP is attempting to recover losses for investors in this securities lawsuit. To respond to this press release, contact us at (212) 363-7576 or email us at [email protected]. For more information about the lawsuit, please visit www.zlk.com/pslra-1/bioage-labs-inc-loss-submission-form?id=1920.
NOTE: If you are unable to access this link, please provide Levi & Korsinsky, LLP with your contact information, and they will reach out to you.
Forward-Looking Statements: Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include, but are not limited to, statements related to the progress, timing, and potential outcome of the BioAge securities lawsuit. These statements involve a number of risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the possibility that the securities class action will not be certified, the ability of the Company to defend against the allegations, the ability of the plaintiffs to prove their case, and the ability to recover damages.
